Skip to content

Neuropace, Inc. NPCE Net Change in Cash

Net Change in Cash at other companies

Medtronic logo
MedtronicMDT
-$136M+11.7%
LivaNova logo
LivaNovaLIVN
-$95.85M-744%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$10.46M-35.5%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
-$5.88M+93.9%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$35.76M+241%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$17M-55.2%

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s net change in cash?
Neuropace, Inc. (NPCE) reported net change in cash of -$6.18M in Q1 2026.
How has Neuropace, Inc.'s net change in cash changed year-over-year?
Neuropace, Inc.'s net change in cash decreased by 145.5% year-over-year, from $13.59M to -$6.18M.
What is the long-term trend for Neuropace, Inc.'s net change in cash?
Over 2 years (2021 to 2023), Neuropace, Inc.'s net change in cash has grown at a 24.0% compound annual growth rate (CAGR), from -$7.45M to $11.45M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.